HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NYXH
Nyxoah S.A.
There isn't enough reported data to score NYXH yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NYXH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
NYXH's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NYXH PE Valuation
NYXH has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NYXH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect NYXH's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over NYXH on earnings, with more consistent year-over-year improvement.
NYXH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.41 | -$0.07 |
| Q1 2026 | -$2.38 | -$0.17 |
| Q4 2025 | -$2.63 | -$0.62 |
| Q3 2025 | -$2.49 | -$0.57 |
| Q2 2025 | -$2.34 | -$0.67 |
| Q1 2025 | -$2.21 | -$0.52 |
| Q4 2024 | -$2.01 | -$0.28 |
| Q3 2024 | -$1.92 | -$0.04 |
NYXH lost $2.41 per share over the past year, about the same as its loss the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NYXH on profitability, with a higher operating margin.
NYXH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.5M | +473% |
| Q1 2026 | $8.2M | +592% |
| Q4 2025 | $6.3M | +347% |
| Q3 2025 | $2.2M | +56% |
| Q2 2025 | $1.5M | +74% |
| Q1 2025 | $1.2M | -13% |
| Q4 2024 | $1.4M | -31% |
| Q3 2024 | $1.4M | +30% |
NYXH's revenue has grown year over year for five quarters in a row: $9M last quarter, up 473% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -268% | +1213 points |
| Q1 2026 | -322% | +1617 points |
| Q4 2025 | -324% | +1126 points |
| Q3 2025 | -1227% | -44 points |
| Q2 2025 | -1481% | +245 points |
| Q1 2025 | -1940% | -940 points |
| Q4 2024 | -1450% | -856 points |
| Q3 2024 | -1183% | -58 points |
NYXH's operating margin was −268% last quarter, up 1213 points from the same quarter a year ago, near the top of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NYXH on cash generation, producing positive trailing cash flow while its opponent burns cash.
NYXH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$19.8M | -$639.9K |
| Q1 2026 | -$24.8M | -$4M |
| Q4 2025 | -$14.6M | +$682K |
| Q3 2025 | -$22.8M | -$7M |
| Q2 2025 | -$19.2M | -$5.2M |
| Q1 2025 | -$20.8M | -$4.5M |
| Q4 2024 | -$15.3M | -$369.9K |
| Q3 2024 | -$15.8M | -$40K |
NYXH has burned cash in almost every quarter: −$82M over the past year, against −$71M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NYXH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NYXH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +32% | +13.8M shares |
| 1 year | +52% | +19.6M shares |
| 3 years | +99% | +28.4M shares |
| 5 years | +158% | +34.9M shares |
| Available history | +376% | +45M shares |
NYXH has 57M diluted shares, up 52% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NYXH hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NYXH Net Leverage
NYXH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NYXH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.6 | Oversold |
| Stochastic | 6.9 | Oversold |
NYXH's weekly RSI is 27 (oversold) and its Stochastic is 7 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NYXH PE vs Healthcare Sector
NYXH has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NYXH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.09 | 17% below |
| 20 week MA | $1.37 | 34% below |
| 50 week MA | $2.70 | 67% below |
| 100 week MA | $5.04 | 82% below |
| 200 week MA | $6.61 | 86% below |
NYXH is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NYXH on returns for 2026, with the stronger performance.
NYXH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.0 | $21.0 | -12% |
| 2022 | $21.0 | $5.20 | -75% |
| 2023 | $5.20 | $4.64 | -11% |
| 2024 | $4.64 | $8.00 | +72% |
| 2025 | $8.00 | $4.47 | -44% |
| 2026 YTD | $4.47 | $0.90 | -80% |
NYXH has finished lower in four of the last five years. It's down 80% so far in 2026.